SCHEMBL9924255

SCHEMBL9924255

CCOC(=O)NC1CCC(N/C(=N\C(=O)c2ccc(C)cc2)Nc2cc(F)cc(Cl)c2)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.36
EPHX2 P34913 3/20 0.35
MC5R P33032 1/20 0.35
KMT2A Q03164 4/20 0.35
HSD11B1 P28845 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
MAPT P10636 2/20 0.34
USP2 O75604 1/20 0.34
TSHR P16473 1/20 0.34
DRD2 P14416 1/20 0.34
ALPL P05186 1/20 0.34
MEN1 O00255 3/20 0.34
SLC6A9 P48067 1/20 0.34
SLC6A5 Q9Y345 1/20 0.34
SSTR5 P35346 1/20 0.34
CHRM3 P20309 1/20 0.33
OPRK1 P41145 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924087 0.95 HSD11B1 (0.39) GRM4EPHX2MC5RKMT2AHSD11B1
SCHEMBL9924077 0.93 GRM4 (0.38) GRM4EPHX2KMT2AHSD11B1MAPT
SCHEMBL9924329 0.92 SLC6A9 (0.40) EPHX2KMT2AHSD11B1MAPTSLC6A9
SCHEMBL17206702 0.92 CHRM1 (0.38) GRM4EPHX2MC5RKMT2AHSD11B1
SCHEMBL9924228 0.92 CHRM1 (0.38) GRM4EPHX2MC5RKMT2AHSD11B1
SCHEMBL9924259 0.92 CHRM1 (0.38) GRM4EPHX2MC5RKMT2AHSD11B1
SCHEMBL9924069 0.92 GRM4 (0.38) GRM4MC5RKMT2AMAPTUSP2
SCHEMBL9924084 0.91 GRM4 (0.35) GRM4EPHX2MC5RKMT2AHSD11B1
SCHEMBL9924256 0.90 NPC1 (0.36) GRM4EPHX2KMT2ADRD2MEN1
SCHEMBL9924254 0.90 CHRM1 (0.39) GRM4EPHX2MC5RKMT2AHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed